MONTGOMERY, Texas — (BUSINESS WIRE,October 11, 2016 09:00 AM Eastern Daylight Time) — AngioSoma, Inc. (OTCQB: SOAN) filed three (3) new patent applications associated with Liprostin™, adding to the Company’s product pipeline and supplementing the intellectual property already conveyed by Chairman Emeritus Dr. David P. “Doc” Summers, PhD, FACA. The new patents include transdermal skin patches and other methods of treating atherosclerosis, commonly called Peripheral Artery Disease (‘PAD’) and Coronary Artery Disease (‘CAD’).
“We are strengthening our flagship product Liprostin™, which is a unique liposomal delivery of prostaglandin e1 (‘PGE1’), a naturally occurring hormone to treat the most pervasive and insidious disease in America, PAD – the atherosclerotic buildup of fatty plaque on blood vessel walls causing eventual blockage of blood flow. PAD is the same disease as CAD that causes death by heart attack in coronary arteries,” explained Ms. Alexanderia K Blankenship, CEO & President of AngioSoma, Inc. “We are very fortunate to have a product that has successfully completed its U.S. Food and Drug Administration (‘FDA’) Phase I and II trials, and is ready to enter Phase III trials. We are continuing to develop new ways to treat PAD and CAD, such as with transdermal skin patches and subcutaneous pellets. We have wide ranging intellectual property covering various treatment modalities including atherectomy catheters (plaque scrappers) and drug releasing stents.”
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (http://www.angiosoma.com) is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (‘PAD‘). Our lead pharmaceutical product Liprostin™, a treatment for PAD, has successfully completed FDA Phase I and three Phase II clinical trials, and we are in discussions with several contract research organizations for rapid completion of our U.S. Food and Drug Administration (‘FDA‘) approved protocol for Phase III with submission of our new drug application for marketing in the U.S. and its territories.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.